HRP20210832T1 - Kombinacija trazodona i gabapentina za liječenje boli - Google Patents
Kombinacija trazodona i gabapentina za liječenje boli Download PDFInfo
- Publication number
- HRP20210832T1 HRP20210832T1 HRP20210832TT HRP20210832T HRP20210832T1 HR P20210832 T1 HRP20210832 T1 HR P20210832T1 HR P20210832T T HRP20210832T T HR P20210832TT HR P20210832 T HRP20210832 T HR P20210832T HR P20210832 T1 HRP20210832 T1 HR P20210832T1
- Authority
- HR
- Croatia
- Prior art keywords
- gabapentin
- amount
- salt
- prodrug
- equal
- Prior art date
Links
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 title claims 38
- 229960002870 gabapentin Drugs 0.000 title claims 19
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 title claims 12
- 229960003991 trazodone Drugs 0.000 title claims 12
- 208000002193 Pain Diseases 0.000 title claims 5
- 150000003839 salts Chemical class 0.000 claims 16
- 229940002612 prodrug Drugs 0.000 claims 15
- 239000000651 prodrug Substances 0.000 claims 15
- 239000000825 pharmaceutical preparation Substances 0.000 claims 11
- 229960002359 gabapentin enacarbil Drugs 0.000 claims 7
- TZDUHAJSIBHXDL-UHFFFAOYSA-N gabapentin enacarbil Chemical compound CC(C)C(=O)OC(C)OC(=O)NCC1(CC(O)=O)CCCCC1 TZDUHAJSIBHXDL-UHFFFAOYSA-N 0.000 claims 7
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- 206010065390 Inflammatory pain Diseases 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 206010015150 Erythema Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 208000008765 Sciatica Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 231100000321 erythema Toxicity 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 208000018937 joint inflammation Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 239000011885 synergistic combination Substances 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (11)
1. Farmaceutski pripravak, naznačen time, da obuhvaća sinergističku kombinaciju trazodona ili njegove soli u količini za dobivanje odgovarajuće doze koja je jednaka ili manja od 1 mg/kg, i gabapentina ili njegove soli ili njegovog predlijeka u količini za dobivanje doze koja je jednaka ili manja od 15 mg/kg, te najmanje jedno farmaceutski prihvatljivo pomoćno sredstvo, za uporabu u liječenju boli, pri čemu se navedena bol bira iz skupine koju čine kronična bol, upalna bol i neuropatska bol, gdje spomenuti trazodon i spomenuti gabapentin ostvaruju maseni omjer trazodona prema gabapentinu u rasponu od 1:15 do 1:5 i pritom spomenuti predlijek gabapentina jest gabapentin enakarbil.
2. Farmaceutski pripravak za uporabu prema patentnom zahtjevu 1, naznačen time, da navedeni pripravak sadrži trazodon ili njegovu sol u količini u količini za dobivanje odgovarajuće doze koja je jednaka ili manja od 0,5 mg/kg i gabapentin ili njegovu sol ili njegov predlijek u količini u količini za dobivanje odgovarajuće doze koja je jednaka ili manja od 5 mg/kg.
3. Farmaceutski pripravak za uporabu prema patentnom zahtjevu 1, naznačen time, da navedeni pripravak sadrži trazodon ili njegovu sol u količini u količini za dobivanje odgovarajuće doze koja je jednaka ili manja od 0,2 mg/kg i gabapentin ili njegovu sol ili njegov predlijek u količini u količini za dobivanje odgovarajuće doze koja je jednaka ili manja od 2 mg/kg i pritom spomenuti predlijek gabapentina jest gabapentin enakarbil.
4. Farmaceutski pripravak za uporabu prema patentnom zahtjevu 1, naznačen time, da navedeni pripravak sadrži trazodon ili njegovu sol u količini u količini za dobivanje odgovarajuće doze koja je jednaka iznosu oko 0,15 mg/kg i gabapentin ili njegovu sol ili njegov predlijek u količini u količini za dobivanje odgovarajuće doze koja je jednaka iznosu oko 1,5 mg/kg i pritom spomenuti predlijek gabapentina jest gabapentin enakarbil.
5. Farmaceutski pripravak za uporabu prema patentnom zahtjevu 1, naznačen time, da navedeni pripravak sadrži trazodon ili njegovu sol u količini koja je jednaka ili manja od 70 mg i gabapentin ili njegovu sol ili njegov predlijek u količini koja je jednaka ili manja od 1000 mg i pritom spomenuti predlijek gabapentina jest gabapentin enakarbil.
6. Farmaceutski pripravak za uporabu prema patentnom zahtjevu 1, naznačen time, da navedeni pripravak sadrži trazodon ili njegovu sol u količini koja je jednaka ili manja od 35 mg i gabapentin ili njegovu sol ili njegov predlijek u količini koja je jednaka ili manja od 350 mg i pritom spomenuti predlijek gabapentina jest gabapentin enakarbil.
7. Farmaceutski pripravak za uporabu prema patentnom zahtjevu 1, naznačen time, da navedeni pripravak sadrži trazodon ili njegovu sol u količini koja je jednaka ili manja od 15 mg i gabapentin ili njegovu sol ili njegov predlijek u količini koja je jednaka ili manja od 150 mg i pritom spomenuti predlijek gabapentina jest gabapentin enakarbil.
8. Farmaceutski pripravak za uporabu prema bilo kojem od prethodnih patentnih zahtjeva 1 do 7, naznačen time, da navedeni pripravak sadrži količinu trazodona ili njegove soli i količinu gabapentina ili njegove soli ili njegovog predlijeka, tako da se ostvaruje maseni omjer trazodona prema gabapentinu u rasponu od oko 1:10 i pritom spomenuti predlijek gabapentina jest gabapentin enakarbil.
9. Farmaceutski pripravak za uporabu prema bilo kojem od prethodnih patentnih zahtjeva 1 do 8, naznačen time, da služi u liječenju kronične boli.
10. Farmaceutski pripravak za uporabu prema bilo kojem od prethodnih patentnih zahtjeva 1 do 8, naznačen time, da je navedena upalna bol izazvana putem edema, eritema, zglobne upale, osteoartritisa, reumatoidnog artritisa i artroze.
11. Farmaceutski pripravak za uporabu prema bilo kojem od prethodnih patentnih zahtjeva 1 do 8, naznačen time, da je navedena neuropatska bol izazvana putem dijabetesa, raka, imunodeficijencije, ozljede, ishemije, multiple skleroze, išijasa, trigeminalne neuralgije, fibromialgije i postherpetičnog sindroma.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15191024 | 2015-10-22 | ||
| PCT/EP2016/074835 WO2017067870A1 (en) | 2015-10-22 | 2016-10-17 | Combination of trazodone and gabapentin for the treatment of pain |
| EP16781816.0A EP3364975B1 (en) | 2015-10-22 | 2016-10-17 | Combination of trazodone and gabapentin for the treatment of pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210832T1 true HRP20210832T1 (hr) | 2021-08-06 |
Family
ID=54345445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210832TT HRP20210832T1 (hr) | 2015-10-22 | 2021-05-24 | Kombinacija trazodona i gabapentina za liječenje boli |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US10786498B2 (hr) |
| EP (2) | EP3881845A3 (hr) |
| JP (1) | JP6924184B2 (hr) |
| KR (1) | KR20180063314A (hr) |
| CN (1) | CN108174599B (hr) |
| AR (1) | AR106415A1 (hr) |
| AU (1) | AU2016341063B2 (hr) |
| BR (1) | BR112018007374B1 (hr) |
| CA (1) | CA2999389C (hr) |
| CY (1) | CY1124229T1 (hr) |
| DK (1) | DK3364975T3 (hr) |
| EA (2) | EA202190626A3 (hr) |
| ES (1) | ES2879392T3 (hr) |
| GE (1) | GEP20207145B (hr) |
| HK (1) | HK1252359A1 (hr) |
| HR (1) | HRP20210832T1 (hr) |
| HU (1) | HUE054653T2 (hr) |
| IL (1) | IL258316B (hr) |
| LT (1) | LT3364975T (hr) |
| MD (1) | MD3364975T2 (hr) |
| MX (1) | MX2018004532A (hr) |
| PL (1) | PL3364975T3 (hr) |
| PT (1) | PT3364975T (hr) |
| RS (1) | RS61989B1 (hr) |
| SI (1) | SI3364975T1 (hr) |
| UA (1) | UA122245C2 (hr) |
| WO (1) | WO2017067870A1 (hr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT201900006602A1 (it) | 2019-05-07 | 2020-11-07 | Acraf | Composizione farmaceutica per il trattamento del dolore neuropatico |
| EP3907214A1 (en) * | 2020-05-04 | 2021-11-10 | Dompe' Farmaceutici S.P.A. | Co-crystal of ketoprofen, lysine and gabapentin, pharmaceutical compositions and their medical use |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2006107534A (ru) * | 2003-09-12 | 2007-09-20 | Уорнер-Ламберт Компани Ллс (Us) | Комбинация, включающая альфа-2-дельта-лиганд анд и ssri и/или snri, для лечения депрессии и тревожного расстройства |
| KR100828218B1 (ko) | 2003-09-12 | 2008-05-07 | 화이자 인코포레이티드 | 알파-2-델타 리간드 및 세로토닌/노르아드레날린 재흡수 억제제를 포함하는 조합물 |
| WO2006069293A2 (en) | 2004-12-22 | 2006-06-29 | Friedman Robert S | Composition comprising n-acetylcysteine and further pain or anti- inflamm medications |
| US20120083508A1 (en) | 2006-12-22 | 2012-04-05 | Allergan, Inc. | Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain |
| JP5328787B2 (ja) * | 2007-07-18 | 2013-10-30 | ダウ グローバル テクノロジーズ エルエルシー | 水−グリコール液圧流体組成物 |
| EP2184986A4 (en) * | 2007-08-06 | 2010-12-15 | Trinity Lab Inc | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHRONIC PAIN AND PAIN RELATING TO NEUROPATHY |
| WO2010003046A2 (en) * | 2008-07-02 | 2010-01-07 | Teva Pharmaceutical Industries Ltd. | Gabapentin enacarbil salts and processes for their preparation |
| KR20130002292A (ko) | 2011-06-28 | 2013-01-07 | 주식회사 비보존 | 다중 타겟팅의 상승 효과를 유발하는 유효물질의 조합 및 그 용도 |
-
2016
- 2016-10-17 AU AU2016341063A patent/AU2016341063B2/en active Active
- 2016-10-17 PT PT167818160T patent/PT3364975T/pt unknown
- 2016-10-17 EP EP21158825.6A patent/EP3881845A3/en active Pending
- 2016-10-17 DK DK16781816.0T patent/DK3364975T3/da active
- 2016-10-17 IL IL258316A patent/IL258316B/en unknown
- 2016-10-17 KR KR1020187013499A patent/KR20180063314A/ko not_active Application Discontinuation
- 2016-10-17 US US15/767,543 patent/US10786498B2/en active Active
- 2016-10-17 PL PL16781816T patent/PL3364975T3/pl unknown
- 2016-10-17 ES ES16781816T patent/ES2879392T3/es active Active
- 2016-10-17 EP EP16781816.0A patent/EP3364975B1/en active Active
- 2016-10-17 CA CA2999389A patent/CA2999389C/en active Active
- 2016-10-17 CN CN201680059627.1A patent/CN108174599B/zh active Active
- 2016-10-17 EA EA202190626A patent/EA202190626A3/ru unknown
- 2016-10-17 HU HUE16781816A patent/HUE054653T2/hu unknown
- 2016-10-17 JP JP2018519360A patent/JP6924184B2/ja active Active
- 2016-10-17 MX MX2018004532A patent/MX2018004532A/es unknown
- 2016-10-17 GE GEAP201614778A patent/GEP20207145B/en unknown
- 2016-10-17 RS RS20210740A patent/RS61989B1/sr unknown
- 2016-10-17 SI SI201631218T patent/SI3364975T1/sl unknown
- 2016-10-17 WO PCT/EP2016/074835 patent/WO2017067870A1/en active Application Filing
- 2016-10-17 BR BR112018007374-1A patent/BR112018007374B1/pt active IP Right Grant
- 2016-10-17 EA EA201890911A patent/EA037838B1/ru unknown
- 2016-10-17 LT LTEP16781816.0T patent/LT3364975T/lt unknown
- 2016-10-17 MD MDE20180825T patent/MD3364975T2/ro unknown
- 2016-10-17 UA UAA201804930A patent/UA122245C2/uk unknown
- 2016-10-20 AR ARP160103200A patent/AR106415A1/es unknown
-
2018
- 2018-09-11 HK HK18111645.6A patent/HK1252359A1/zh unknown
-
2020
- 2020-04-15 US US16/849,545 patent/US11752147B2/en active Active
-
2021
- 2021-05-24 HR HRP20210832TT patent/HRP20210832T1/hr unknown
- 2021-06-18 CY CY20211100546T patent/CY1124229T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210832T1 (hr) | Kombinacija trazodona i gabapentina za liječenje boli | |
| EP4218819A3 (en) | Combination therapy based on pd-1 signal inhibitors | |
| HRP20171570T1 (hr) | Tapentadol za sprječavanje i liječenje depresije i tjeskobe | |
| FI3355889T3 (fi) | Diaminopyrimidiini-p2x3- ja p2x2/3-reseptorimodulaattoreita käytettäväksi yskän hoidossa | |
| WO2013100882A3 (en) | Combinations of diacerein and non-steroidal inflammation drugs | |
| MX2017013636A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas. | |
| HRP20210552T1 (hr) | Liječenje multiplog mijeloma (mm) | |
| HRP20220903T1 (hr) | Seladelpar za liječenje primarnog bilijarnog kolangitisa | |
| NZ736978A (en) | Salts and prodrugs of 1-methyl-d-tryptophan | |
| MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. | |
| JP2017512194A5 (hr) | ||
| JP2017507142A5 (hr) | ||
| WO2015152577A3 (ko) | 골 질환 예방 및 치료용 조성물 | |
| MX2016010892A (es) | Agente para suprimir el progreso de o para mejorar la enfermedad renal cronica. | |
| WO2017106367A8 (en) | Method of treating neurodegenerative disorders by rescuing alpha-synuclein toxicity | |
| MX2017013633A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas. | |
| RU2016149776A (ru) | ЛЕЧЕНИЕ ИММУННЫХ, ВОСПАЛИТЕЛЬНЫХ И ДЕГЕНЕРАТИВНЫХ АРТРИТОВ С ПОМОЩЬЮ ОЛОВА-117m | |
| MX348595B (es) | Composicion farmaceutica con agentes antiinflamatorios y proceso de produccion. | |
| AR102295A1 (es) | Compuesto derivado de pirazolina y su uso en un régimen de dosificación semanal contra inflamación y dolor derivados de enfermedad articular degenerativa en mamíferos | |
| BR112017022335A2 (pt) | combinação de dose fixa inviolável que fornece rápida liberação de dois fármacos a partir de partículas e matriz | |
| WO2015166418A3 (es) | Composición farmacéutica para el tratamiento de alopatías relacionadas con el dolor, usando como agente activo al ketorolaco trometamina y clorhidrato de tramadol | |
| MX2018011685A (es) | Proceso para formulaciones solidas de mesalazina. | |
| MX2018011142A (es) | Combinacion farmaceutica sinergica de un inhibidor selectivo de la ciclooxigenasa 2 y un derivado de antraquinona. | |
| CL2017000026A1 (es) | Formas de dosificación farmacéutica | |
| HRP20171922T1 (hr) | Farmaceutski pripravak koji sadrži (1r,4r)-6'-fluoro-n,n-dimetil-4-fenil-4',9'-dihidro-3'h-spiro[cikloheksan-1,1'-pirano [3,4,b]indol]-4-amin i duloksetin |